Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

Mult Scler Relat Disord. 2020 Oct:45:102442. doi: 10.1016/j.msard.2020.102442. Epub 2020 Aug 4.

Abstract

Background: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS).

Objectives: to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment.

Methods: Case series.

Results: Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae.

Conclusion: Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.

Keywords: COVID-19; DMD; DMT; Disease modifying therapies; IL-6; MS.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections / complications*
  • Coronavirus Infections / immunology
  • Female
  • Humans
  • Immunocompromised Host*
  • Immunologic Factors / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Sclerosis / complications*
  • Multiple Sclerosis / drug therapy*
  • Pandemics
  • Pneumonia / immunology
  • Pneumonia / virology
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / immunology
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • ocrelizumab